Due to its reliance on CYP3A4, co-administration with potent inhibitors such as erythromycin, ketoconazole, or GFJ may substantially increase plasma concentrations, elevating the risk of muscle-related adverse events, including rhabdomyolysis [20,114]. This evidence concerns the gene CYP3A4 and rhabdomyolysis.